Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 13
1966 20
1967 18
1968 16
1969 23
1970 30
1971 17
1972 26
1973 24
1974 14
1975 14
1976 15
1977 20
1978 21
1979 25
1980 17
1981 30
1982 33
1983 26
1984 24
1985 34
1986 24
1987 43
1988 69
1989 44
1990 52
1991 28
1992 59
1993 52
1994 49
1995 48
1996 48
1997 71
1998 64
1999 64
2000 66
2001 89
2002 93
2003 90
2004 125
2005 103
2006 134
2007 155
2008 170
2009 151
2010 207
2011 234
2012 241
2013 298
2014 310
2015 346
2016 341
2017 308
2018 322
2019 189
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

4,741 results
Results by year
Filters applied: . Clear all
Page 1
Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis.
Singh S, et al. Aliment Pharmacol Ther 2018 - Review. PMID 29205406 Free article.
BACKGROUND: There are limited data to inform positioning of agents for treating moderate-severe ulcerative colitis (UC). AIM: To assess comparative efficacy and safety of different therapies as first-line (biologic-naïve) and second-line (prior exposure to anti-tumour necrosis factor(TNF)-α) agents for moderate-severe UC, through a systematic review and network meta-analysis, and appraise quality of evidence (QoE) using grading of recommendations, assessment, development and evaluation (GRADE) approach. ...Differences in trial design limited comparability of trials of maintenance therapy for efficacy. Vedolizumab was ranked safest in terms of serious adverse events (SUCRA, 0.91), and infection (SUCRA, 0.75) in maintenance trials. ...
BACKGROUND: There are limited data to inform positioning of agents for treating moderate-severe ulcerative colitis (UC). AIM: …
[Golimumab Therapy in Ulcerative Colitis].
Moon W. Korean J Gastroenterol 2016 - Review. PMID 26907481 Korean. Free article.
Ulcerative colitis is a chronic inflammatory condition of the colon, characterized by diffuse mucosal inflammation and blood-mixed diarrhea. ...This review will focus on golimumab therapy in ulcerative colitis....
Ulcerative colitis is a chronic inflammatory condition of the colon, characterized by diffuse mucosal inflammation and blood-m
The long-term effects of probiotics in the therapy of ulcerative colitis: A clinical study.
Palumbo VD, et al. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2016 - Clinical Trial. PMID 27623957 Free article.
The present study evaluates the long-term (2 years) effects of combination therapy (mesalazine plus a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4) on ulcerative colitis activity. ...CONCLUSIONS: A long-term treatment modality of anti-inflammatory drugs and probiotics is viable and could be an alternative to corticosteroids in mild-to moderate ulcerative colitis....
The present study evaluates the long-term (2 years) effects of combination therapy (mesalazine plus a probiotic blend of Lactobacillu …
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease.
Bermejo F, et al. Gastroenterol Hepatol 2018 - Review. PMID 29357999
They are mainly used to maintain remission in steroid-dependent disease or with ciclosporin to control a severe ulcerative colitis flare-up, as well as to prevent postoperative Crohn's disease recurrence, and also in combination therapy with biologics. ...Non-melanoma skin cancer, lymphomas and urinary tract tumours have been linked to thiopurine therapy. Thiopurine use is safe during conception, pregnancy and breastfeeding....
They are mainly used to maintain remission in steroid-dependent disease or with ciclosporin to control a severe ulcerative colitis
Systematic review and network meta-analysis of treatment for moderate-to-severe ulcerative colitis.
Trigo-Vicente C, et al. Int J Clin Pharm 2018. PMID 30478492
For induction therapy, infliximab was the best drug for induction of clinical response and remission, while ozanimod showed to be the best for induction of mucosal healing. ...Conclusion This network meta-analysis suggests infliximab may be the best therapeutic option for moderate-to-severe ulcerative colitis. ...
For induction therapy, infliximab was the best drug for induction of clinical response and remission, while ozanimod showed to …
Severe ulcerative colitis: predictors of response and algorithm proposal for rescue therapy.
Ribaldone DG, et al. Ir J Med Sci 2018. PMID 28756540 Free article.
BACKGROUND: There is no agreeing if rescue therapy can avoid short-term colectomy in patients treated for severe steroid-refractory ulcerative colitis. ...The predictors analysed were gender, age, time from ulcerative colitis diagnosis, months of steroid or/and azathioprine therapy before onset of the severe phase, smoking habits, extension of the disease, laboratory analyses and Mayo score. ...
BACKGROUND: There is no agreeing if rescue therapy can avoid short-term colectomy in patients treated for severe steroid-refractory …
Biological therapy for ulcerative colitis: an update.
Seo GS and Chae SC. World J Gastroenterol 2014 - Review. PMID 25309060 Free PMC article.
Of the diverse biological agents used for patients with ulcerative colitis, the anti-tumor necrosis factor-α agents infliximab and adalimumab have been used in large-scale clinical trials and are currently widely used in the treatment of inflammatory bowel disease patients. Recent studies have indicated that golimumab, oral tofacitinib and vedolizumab reportedly achieved good clinical response and remission rates in ulcerative colitis patients. ...
Of the diverse biological agents used for patients with ulcerative colitis, the anti-tumor necrosis factor-α agents infliximab …
Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis.
Vickers AD, et al. PLoS One 2016 - Review. PMID 27776175 Free PMC article.
BACKGROUND: Biological therapies are increasingly used to treat ulcerative colitis (UC). AIM: To compare the efficacy of biologics in adults with moderately-to-severely active UC, stratified by prior exposure to anti-tumour necrosis factor (anti-TNF) therapy. ...In anti-TNF therapy-experienced patients, only vedolizumab and adalimumab could be compared. At induction, no significant differences in efficacy were seen. ...
BACKGROUND: Biological therapies are increasingly used to treat ulcerative colitis (UC). AIM: To compare the efficacy of biolo …
Safety of biological therapies in ulcerative colitis: An umbrella review of meta-analyses.
Bonovas S, et al. Best Pract Res Clin Gastroenterol 2018 - Review. PMID 30060938
Biological agents have proven clinical efficacy in the treatment of ulcerative colitis (UC). Their adverse effects have also been studied in a substantial number of primary studies and meta-analyses. ...
Biological agents have proven clinical efficacy in the treatment of ulcerative colitis (UC). Their adverse effects have also b …
Cyclosporine in severe ulcerative colitis refractory to steroid therapy.
Lichtiger S, et al. N Engl J Med 1994 - Clinical Trial. PMID 8196726 Free article.
BACKGROUND: There has been no new effective drug therapy for patients with severe ulcerative colitis since corticosteroids were introduced almost 40 years ago. In an uncontrolled study, 80 percent of 32 patients with active ulcerative colitis refractory to corticosteroid therapy had a response to cyclosporine therapy. ...
BACKGROUND: There has been no new effective drug therapy for patients with severe ulcerative colitis since corti …
4,741 results
Jump to page
Feedback